CN109963844A - 一类抑制并降解酪氨酸蛋白激酶alk的化合物 - Google Patents

一类抑制并降解酪氨酸蛋白激酶alk的化合物 Download PDF

Info

Publication number
CN109963844A
CN109963844A CN201880004044.8A CN201880004044A CN109963844A CN 109963844 A CN109963844 A CN 109963844A CN 201880004044 A CN201880004044 A CN 201880004044A CN 109963844 A CN109963844 A CN 109963844A
Authority
CN
China
Prior art keywords
substituent group
alkyl
integer
independently selected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004044.8A
Other languages
English (en)
Other versions
CN109963844B (zh
Inventor
舒永志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Yongmei Pharmaceutical Technology Co.,Ltd.
Original Assignee
Shanghai Meizer Pharmaceuticals Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Meizer Pharmaceuticals Co ltd filed Critical Shanghai Meizer Pharmaceuticals Co ltd
Publication of CN109963844A publication Critical patent/CN109963844A/zh
Application granted granted Critical
Publication of CN109963844B publication Critical patent/CN109963844B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

本发明提供了一类抑制并降解酪氨酸蛋白激酶ALK的化合物，具体地，本发明提供了一种如下式I所示的化合物；其中，各基团的定义如说明书中所述。本发明的化合物具有很好的间变性淋巴瘤激酶(ALK)抑制活性，可以用于制备治疗间ALK活性相关的疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880004044.8A 2017-09-03 2018-09-02 一类抑制并降解酪氨酸蛋白激酶alk的化合物 Active CN109963844B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017107830670 2017-09-03
CN201710783067.0A CN109422733A (zh) 2017-09-03 2017-09-03 一类抑制并降解酪氨酸蛋白激酶alk的化合物
PCT/CN2018/103709 WO2019042444A1 (zh) 2017-09-03 2018-09-02 一类抑制并降解酪氨酸蛋白激酶alk的化合物

Publications (2)

Publication Number Publication Date
CN109963844A true CN109963844A (zh) 2019-07-02
CN109963844B CN109963844B (zh) 2022-08-12

Family

ID=65512797

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710783067.0A Pending CN109422733A (zh) 2017-09-03 2017-09-03 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CN201880004044.8A Active CN109963844B (zh) 2017-09-03 2018-09-02 一类抑制并降解酪氨酸蛋白激酶alk的化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710783067.0A Pending CN109422733A (zh) 2017-09-03 2017-09-03 一类抑制并降解酪氨酸蛋白激酶alk的化合物

Country Status (3)

Country Link
US (1) US11485726B2 (zh)
CN (2) CN109422733A (zh)
WO (1) WO2019042444A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089400A1 (zh) * 2020-10-26 2022-05-05 上海美志医药科技有限公司 靶向降解Btk的化合物及其抗肿瘤用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
KR20210003804A (ko) * 2018-04-13 2021-01-12 아비나스 오퍼레이션스, 인코포레이티드 세레브론 리간드 및 이를 포함하는 2작용성 화합물
CN110684015A (zh) * 2018-07-06 2020-01-14 四川大学 靶向alk的protac及其应用
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
JP7426124B2 (ja) * 2019-06-12 2024-02-01 シャンハイテック ユニバーシティ Ａｌｋタンパク質レギュレーター、及びその抗腫瘍における使用
US20220306659A1 (en) * 2019-08-23 2022-09-29 Beijing Tide Pharmaceutical Co., Ltd. Compound inhibiting and inducing degradation of egfr and alk
US20230265116A1 (en) * 2020-07-16 2023-08-24 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
CN111892578B (zh) * 2020-08-03 2023-10-20 沈阳药科大学 一种靶向降解黏着斑激酶的化合物及应用
WO2022171123A1 (en) * 2021-02-10 2022-08-18 Beigene, Ltd. Egfr degraders and methods of use
WO2022242725A1 (zh) * 2021-05-19 2022-11-24 和径医药科技（上海）有限公司 一类新型蛋白降解剂及其应用
EP4359403A1 (en) * 2021-06-21 2024-05-01 BeiGene Switzerland GmbH (r) -glutarimide crbn ligands and methods of use
KR20240029036A (ko) 2021-06-25 2024-03-05 징 메디슨 테크놀로지 (상하이) 엘티디. 단백질 억제제 또는 분해제, 이를 포함하는 약학적 조성물 및 의학적 용도
CN113735828B (zh) * 2021-09-07 2022-10-28 南方医科大学 一种靶向降解egfr的化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN104876914A (zh) * 2014-02-28 2015-09-02 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN106146468A (zh) * 2015-04-17 2016-11-23 杭州雷索药业有限公司 吡啶酮类蛋白激酶抑制剂
WO2016192132A1 (zh) * 2015-06-04 2016-12-08 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016013563A (es) * 2014-04-14 2017-05-09 Arvinas Inc Moduladores de la proteolisis basados en imida y metodos de uso asociados.
CN106336382B (zh) * 2015-07-06 2022-04-05 杭州雷索药业有限公司 4-饱和环基取代的苯胺类蛋白激酶抑制剂
WO2017011371A1 (en) * 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
KR101825065B1 (ko) * 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN109422752B (zh) * 2017-09-03 2023-04-07 上海美志医药科技有限公司 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
CN109516989B (zh) * 2017-09-17 2021-12-31 上海美志医药科技有限公司 一类抑制并降解cdk的化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN104876914A (zh) * 2014-02-28 2015-09-02 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN106146468A (zh) * 2015-04-17 2016-11-23 杭州雷索药业有限公司 吡啶酮类蛋白激酶抑制剂
WO2016192132A1 (zh) * 2015-06-04 2016-12-08 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089400A1 (zh) * 2020-10-26 2022-05-05 上海美志医药科技有限公司 靶向降解Btk的化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
WO2019042444A1 (zh) 2019-03-07
CN109963844B (zh) 2022-08-12
CN109422733A (zh) 2019-03-05
US20200199106A1 (en) 2020-06-25
US11485726B2 (en) 2022-11-01

Similar Documents

Publication Publication Date Title
CN109963844A (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CN109422752A (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
CN109952304A (zh) 一类抑制并降解cdk的化合物
TWI710552B (zh) 作為神經元組織胺受體－３拮抗劑之化合物及其用途
EP3283486B1 (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
CN110317192A (zh) 一类具有降解雄激素受体活性的化合物
US9018216B2 (en) Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
TWI534149B (zh) Using imidazo and Anti-tumor effect enhancer for compounds
BRPI0609962A2 (pt) composição farmacêutica oral, e, método para tratar um distúrbio em um mamìfero
WO2012011840A1 (ru) Циклические ν,ν'-диарилтиомочевины и ν,ν'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения
BR112013017985A2 (pt) formas sólidas de inibidor de girase (r) 1-etil-3-[6-flúor-5-[2-(1-hidróxi-1-metil-etil)pirimidin-5-il]-7-(tetra-hidrofuran-2-il)-1h-benzimidazol-2-il]ureia
WO2018084321A1 (ja) Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
JP6850361B2 (ja) キナーゼを選択的に阻害する化合物及びその使用
US10899744B2 (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
CN113490669B (zh) 一类具有降解Btk活性的化合物
CN109963853A (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CN109937203A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
KR20230044416A (ko) Parp 억제제로서의 인돌로 헵타밀 옥심 유사체 결정 및 그의 제조방법
US9453003B2 (en) Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
CN115785107A (zh) 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
TW202115070A (zh) 新穎的egfr抑制劑
JP2004115458A (ja) ２−（３−ニトロベンゾイル）安息香酸誘導体を有効成分とする医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240408

Address after: Unit 1601-1, 16th Floor, Zhongxin Ecological Building, No. 2 Keying Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215127

Patentee after: Suzhou Yongmei Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: 201313 118, 20, 1-42 Lane 83, Hongxiang North Road, Wanxiang Town, Pudong New Area, Shanghai.

Patentee before: SHANGHAI MEIZER PHARMACEUTICALS Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right